180 related articles for article (PubMed ID: 16409295)
1. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.
Rinaldi A; Kwee I; Taborelli M; Largo C; Uccella S; Martin V; Poretti G; Gaidano G; Calabrese G; Martinelli G; Baldini L; Pruneri G; Capella C; Zucca E; Cotter FE; Cigudosa JC; Catapano CV; Tibiletti MG; Bertoni F
Br J Haematol; 2006 Feb; 132(3):303-16. PubMed ID: 16409295
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
3. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
4. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Yuan Y; Liu H; Sahin A; Dai JL
Int J Cancer; 2005 Feb; 113(4):654-9. PubMed ID: 15455373
[TBL] [Abstract][Full Text] [Related]
6. Syk-dependent mTOR activation in follicular lymphoma cells.
Leseux L; Hamdi SM; Al Saati T; Capilla F; Recher C; Laurent G; Bezombes C
Blood; 2006 Dec; 108(13):4156-62. PubMed ID: 16912221
[TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
[TBL] [Abstract][Full Text] [Related]
8. Progressive loss of Syk and abnormal proliferation in breast cancer cells.
Moroni M; Soldatenkov V; Zhang L; Zhang Y; Stoica G; Gehan E; Rashidi B; Singh B; Ozdemirli M; Mueller SC
Cancer Res; 2004 Oct; 64(20):7346-54. PubMed ID: 15492255
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation leads to silencing of the SYK gene in human breast cancer.
Yuan Y; Mendez R; Sahin A; Dai JL
Cancer Res; 2001 Jul; 61(14):5558-61. PubMed ID: 11454707
[TBL] [Abstract][Full Text] [Related]
10. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells.
Coopman PJ; Do MT; Barth M; Bowden ET; Hayes AJ; Basyuk E; Blancato JK; Vezza PR; McLeskey SW; Mangeat PH; Mueller SC
Nature; 2000 Aug; 406(6797):742-7. PubMed ID: 10963601
[TBL] [Abstract][Full Text] [Related]
11. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
Li J; Sidell N
Int J Cancer; 2005 Oct; 117(1):14-20. PubMed ID: 15880583
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
13. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.
Travert M; Huang Y; de Leval L; Martin-Garcia N; Delfau-Larue MH; Berger F; Bosq J; Brière J; Soulier J; Macintyre E; Marafioti T; de Reyniès A; Gaulard P
Blood; 2012 Jun; 119(24):5795-806. PubMed ID: 22510872
[TBL] [Abstract][Full Text] [Related]
14. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.
Wessendorf S; Schwaenen C; Kohlhammer H; Kienle D; Wrobel G; Barth TF; Nessling M; Möller P; Döhner H; Lichter P; Bentz M
Oncogene; 2003 Mar; 22(9):1425-9. PubMed ID: 12618769
[TBL] [Abstract][Full Text] [Related]
15. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
16. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.
Korz C; Pscherer A; Benner A; Mertens D; Schaffner C; Leupolt E; Döhner H; Stilgenbauer S; Lichter P
Blood; 2002 Jun; 99(12):4554-61. PubMed ID: 12036888
[TBL] [Abstract][Full Text] [Related]
17. High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival.
Halldórsdóttir AM; Sander B; Göransson H; Isaksson A; Kimby E; Mansouri M; Rosenquist R; Ehrencrona H
Genes Chromosomes Cancer; 2011 Feb; 50(2):113-21. PubMed ID: 21117067
[TBL] [Abstract][Full Text] [Related]
18. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
Farfsing A; Engel F; Seiffert M; Hartmann E; Ott G; Rosenwald A; Stilgenbauer S; Döhner H; Boutros M; Lichter P; Pscherer A
Leukemia; 2009 Nov; 23(11):2018-26. PubMed ID: 19641524
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of mantle cell lymphoma.
Menanteau MR; Martinez-Climent JA
Methods Mol Biol; 2013; 973():147-63. PubMed ID: 23412788
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes.
Schraders M; Jares P; Bea S; Schoenmakers EF; van Krieken JH; Campo E; Groenen PJ
Br J Haematol; 2008 Oct; 143(2):210-21. PubMed ID: 18699851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
